Peer review reports
From: Tumour inhibitory activity on pancreatic cancer by bispecific nanobody targeting PD-L1 and CXCR4
Original Submission | ||
---|---|---|
26 Apr 2022 | Submitted | Original manuscript |
27 Jun 2022 | Reviewed | Reviewer Report |
8 Aug 2022 | Reviewed | Reviewer Report - Patricia Gaule |
1 Sep 2022 | Author responded | Author comments - Mingyuan Wu |
Resubmission - Version 2 | ||
1 Sep 2022 | Submitted | Manuscript version 2 |
15 Sep 2022 | Author responded | Author comments - Mingyuan Wu |
Resubmission - Version 3 | ||
15 Sep 2022 | Submitted | Manuscript version 3 |
29 Sep 2022 | Reviewed | Reviewer Report |
Resubmission - Version 4 | ||
Submitted | Manuscript version 4 | |
Publishing | ||
4 Oct 2022 | Editorially accepted | |
25 Oct 2022 | Article published | 10.1186/s12885-022-10165-7 |